Skip to main content

Innovative, mechanistic-based strategies for delivery of therapeutic macromolecules across cellular and biological barriers

Objective

Nanomedicine offers capability to significantly change the course of treatment for life-threatening diseases. Many of the most significant current therapeutic targets, to be viable in practice, require the efficient crossing of at least one biological barrier. However, the efficient and controlled crossing of the undamaged barrier is difficult. The range of small molecules that can successfully do so (via diffusive or other non-specific processes) is limited in size and physiochemical properties, greatly restricting the therapeutic strategies that may be applied. In practice, after several decades of limited success, there is a broad consensus that new multi-disciplinary, multi-sectoral strategies are required. Key needs include detailed design and understanding of the bionano-interafce, re-assessment of in vitro models used to assess transport across barriers, and building regulatory considerations into the design phase of nanocarriers.
The overarching premises of the PathChooser ITN are that (i) significant advances can only be made by a more detailed mechanistic understanding of key fundamental endocytotic, transcytotic, and other cellular processes, especially biological barrier crossing; (ii) elucidating the Mode of Action / mechanism of successful delivery systems (beyond current level) will ensure more rapid regulatory and general acceptance of such medicines. Paramount in this is the design and characterization of the in situ interface between the carrier system and the uptake and signalling machinery. (iii) inter-disciplinary knowledge from a range of scientific disciplines is required to launch a genuine attack on the therapeutic challenge. The PathChooser ITN program of research and training will equip the next generation of translational scientists with the tools to develop therapies for a range of currently intractable (e.g. hidden in the brain) and economically unviable diseases (e.g. orphan diseases affecting a limited population).

Call for proposal

FP7-PEOPLE-2013-ITN
See other projects for this call

Coordinator

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Address
Belfield
4 Dublin
Ireland

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Donal Doolan (Mr.)
EU contribution
€ 788 281,78

Participants (8)

SYDDANSK UNIVERSITET
Denmark
EU contribution
€ 284 579,46
Address
Campusvej 55
5230 Odense M

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jan Mollenhauer (Prof.)
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany
EU contribution
€ 222 068,88
Address
Inhoffenstrasse 7
38124 Braunschweig

See on map

Activity type
Research Organisations
Administrative Contact
Michael Straetz (Dr.)
KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 289 456,64
Address
Strand
WC2R 2LS London

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Paul Labbett (Mr.)
E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD
Cyprus
EU contribution
€ 378 437,40
Address
Kosti Palama 34 Aspelia Diam 5
1096 Lefkosia

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Andreani Odysseos (Dr.)
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU contribution
€ 222 068,88
Address
Hofgartenstrasse 8
80539 Munchen

See on map

Activity type
Research Organisations
Administrative Contact
Birgit Knepper-Nicolai (Dr.)
UNIVERSITY OF BRISTOL
United Kingdom
EU contribution
€ 285 056,64
Address
Beacon House Queens Road
BS8 1QU Bristol

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Elodie Mahieu-Wedande (Mrs.)
THE UNIVERSITY OF MANCHESTER
United Kingdom
EU contribution
€ 285 056,64
Address
Oxford Road
M13 9PL Manchester

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Claire Faichnie (Ms.)
AvantiCell Science Ltd
United Kingdom
EU contribution
€ 281 607,70
Address
Gibbsyard Building
KA6 5HW Ayr

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Joanna Oliver (Dr.)